Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer

NACIT is associated with improved DFS for patients with LAGC, whereas NACRT suggests a 'pathology-prognosis mismatch,' where improved pathological response may not reliably predict a survival advantage. These findings challenge the uniform application of pathological response as a surrogate endpoint and highlight the critical need for modality-specific interpretation when evaluating neoadjuvant therapy efficacy.